Some members of the scientific community have concern that they’re coming out of the COVID pandemic—exposure to the virus, ...

The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

B ristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates ...

A new study reveals just how widespread these artificial colorings have become in our food supply. Nearly one in five ...

The American Academy of Neurology issues new guidelines to help clinicians navigate the use of unproven neurologic therapies lacking FDA approval or strong evidence.